These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17509350)

  • 21. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity.
    Christoph F; Moschkowitsch A; Kempkensteffen C; Schostak M; Miller K; Schrader M
    Urol Int; 2007; 79(1):55-9. PubMed ID: 17627170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical treatment of distal ureteral stones.
    Erturhan S; Erbagci A; Yagci F; Celik M; Solakhan M; Sarica K
    Urology; 2007 Apr; 69(4):633-6. PubMed ID: 17445639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double anticholinergic therapy for refractory overactive bladder.
    Bolduc S; Moore K; Lebel S; Lamontagne P; Hamel M
    J Urol; 2009 Oct; 182(4 Suppl):2033-8. PubMed ID: 19695628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
    Urinary Incontinence Treatment Network (UITN)
    Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
    O'Leary MP
    J Urol; 2008 May; 179(5 Suppl):S86. PubMed ID: 18405764
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolterodine for the treatment of daytime incontinence in children.
    Greenfield SP
    J Urol; 2005 Apr; 173(4):1064. PubMed ID: 15758701
    [No Abstract]   [Full Text] [Related]  

  • 30. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial.
    Tehranchi A; Rezaei Y; Khalkhali H; Rezaei M
    Int Braz J Urol; 2013; 39(6):832-40. PubMed ID: 24456787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
    Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
    Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Nijman RJ; Borgstein NG; Ellsworth P; Siggaard C
    Eur Urol; 2007 Nov; 52(5):1511-6. PubMed ID: 17574729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Home uroflowmetry biofeedback in behavioral training for dysfunctional voiding in school-age children: a randomized controlled study.
    Klijn AJ; Uiterwaal CS; Vijverberg MA; Winkler PL; Dik P; de Jong TP
    J Urol; 2006 Jun; 175(6):2263-8; discussion 2268. PubMed ID: 16697850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.